CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
Int J Mol Sci
; 21(24)2020 Dec 15.
Article
in En
| MEDLINE
| ID: mdl-33333768
ABSTRACT
CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 and delineating future perspectives.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
B-Lymphocytes
/
Leukemia, Lymphocytic, Chronic, B-Cell
/
Lymphoma, B-Cell
/
Tetraspanins
/
Antineoplastic Agents, Immunological
/
Immunotherapy
/
Antibodies, Monoclonal
/
Antigens, Neoplasm
Limits:
Humans
Language:
En
Journal:
Int J Mol Sci
Year:
2020
Document type:
Article
Affiliation country: